Completely resected stage IB (>=  cm), II or IIIA non-squamous NSCLC with negative margins; patients may not have received neoadjuvant therapy (chemo- or radio-therapy) for this lung cancer
No locally advanced or metastatic cancer requiring systemic therapy within  years prior to registration; no secondary primary lung cancer diagnosed concurrently or within  years prior to registration
Patients planning to undergo radiation therapy for primary or recurrent carcinomas of the lung or oligo-metastatic carcinoma to the lung; Note: this may be delivered by SBRT or standard fractionation, based on the discretion of the treating physician
Any prior therapy for lung cancer
Any CT imaging findings indicating radiation or drug-induced lung disorders at the time of screening
Any prior therapy for lung cancer
Solid tumor located in central lung
Patient must not have received prior radiation for this lung cancer
Nodal recurrences can be treated on this protocol but prior curative surgery for lung cancer must have been at least  months prior to the nodal recurrence
No prior chemotherapy or radiation for lung cancer
Lung cancer\r\n* Patients with an endobronchial component causing symptoms\r\n* Patients who cannot undergo resection because of poor lung function or distant lung metastasis
No prior hormonal therapy for lung cancer
Central or necrotic lung metastases
The patient has a biopsy-proven radio-opaque (visible by computed tomography [CT]) lung cancer or secondary metastasis to the lung.
Previous radiation therapy to the lung per investigator discretion
Diagnosis of primary lung cancer stage I, II, or IIIa OR secondary lung cancer
Prior systemic therapy or radiation therapy for treatment of the current lung cancer
Received chemotherapy for lung cancer within  months of registration
Patients with isolated lung parenchymal recurrent/persistent NSCLC (histology as defined in eligibility criterion ) after prior definitive surgery or radiotherapy/chemotherapy, when the lesion or lesions are suitable for SABR, are also eligible. Patients with a single metastatic focus in the lung parenchyma with no other lesions are also eligible, because this presentation is challenging to distinguish from recurrent disease. Recurrent disease can be in the same lobe or a different lobe but should not invade critical structures (esophagus, brachial plexus, major vessels, heart, spinal cord); should not involve any lymph node; and should not include any other suspicious lesions in the lung or any other locations. Any prior therapy (surgery, radiotherapy, or systemic) must have been completed at least  weeks before administration of the study drug. Tumors should be =<  cm (measured by computed tomography [CT] imaging in the lung window setting) with NM; positron emission tomography (PET) imaging is required for restaging (per eligibility criterion) and any lymph node suspected of harboring tumor should be confirmed by biopsy (per eligibility criterion)
Patients with direct evidence of regional or distant metastases after appropriate staging studies, or with synchronous non-lung primary or prior non-lung malignancy (other than nonmelanomatous skin cancer or in situ cancer) diagnosed within the past  years are not eligible. Patients with a history of curable non-lung cancer up to  years before registration and have been cancer-free for  years are eligible
Patients must not have elevated lung shunting precluding treatment with Y-
Symptomatic lung disease
All patients must have at least one metastatic or primary lesion within the lung or liver located in an anatomical location amenable to SBRT treatment with  Gy in  fractions, or if not, with either a lung, liver, or adrenal lesion treatable to  Gy in  fractions
>  sites of visceral disease in lung or liver (nonspecific lung nodules =<  cm in diameter are permitted)
Patient has received at least one prior standard chemotherapy or targeted therapy for treatment of lung cancer
Lung function capacity capable of tolerating the proposed lung surgery
Previous surgery for this lung or mediastinum tumor
Patients diagnosed with another lung cancer subtype
Patients who have received prior EGFR treatments for lung cancer
Lung cancer
Patients must meet all SCREENING/PRE-SCREENING and SUB-STUDY REGISTRATION COMMON ELIGIBILITY CRITERIA as specified in S: Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Peripheral lung nodule =<  cm on preoperative CT scan and presumed to be lung cancer; the center of the tumor, as seen on CT, must be located in the outer third of the lung in either the transverse, coronal or sagittal plane; patients with pure ground glass opacities or pathologically confirmed N or N disease are not eligible
Patients must meet all SCREENING/PRE-SCREENING and SUB-STUDY REGISTRATION COMMON ELIGIBILITY CRITERIA as specified in S: Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Patients must meet all SCREENING/PRE-SCREENING and SUB-STUDY REGISTRATION COMMON ELIGIBILITY CRITERIA as specified in S: Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Prior history of lung cancer
Patients must meet all SCREENING/PRE-SCREENING and SUB-STUDY REGISTRATION COMMON ELIGIBILITY CRITERIA as specified in S: Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Patients must meet all SCREENING/PRE-SCREENING and SUB-STUDY REGISTRATION COMMON ELIGIBILITY CRITERIA as specified in S: Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
History of lung inflammation or disease.
Patients must meet all SCREENING/PRE-SCREENING and SUB-STUDY REGISTRATION COMMON ELIGIBILITY CRITERIA as specified in S: Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Prior therapy with any molecular targeted drugs (for lung cancer)
Prior systemic therapy or radiation therapy for treatment of the current lung cancer
Metastatic breast cancer (MBC) OR metastatic non-small cell lung cancer (NSCLC) OR metastatic adenocarcinoma of the prostate; the sites of allowed metastases are: peripheral lung, central lung, mediastinal/cervical lymph node, liver, spinal/paraspinal, osseous, and abdominal-pelvic\r\n* NOTE: after the required number of evaluable patients have been accrued for a given dose level, the accrual for that metastatic location will be temporarily suspended while the safety of that dose level is assessed; a patient can only be entered onto the trial if all of their metastatic locations are open to accrual (e.g. if central lung is temporarily suspended for safety assessment and the patient has a central lung metastases, regardless of other metastases, they cannot enroll until the safety of dose to central lung is determined)
No prior chemotherapy or radiation for this lung cancer.
No previous lung or mediastinal radiation therapy
Prior Therapy: Platinum doublet chemotherapy for current diagnosis of advanced lung cancer. Only one prior line of chemotherapy for advanced lung cancer allowed. Adjuvant chemotherapy, neoadjuvant chemotherapy, or chemoradiotherapy given for early stage lung cancer at least  months prior to diagnosis of recurrent/metastatic disease is not counted as a line of therapy for advanced lung cancer. Patients who received platinum doublet therapy with or without radiotherapy as part of treatment for early stage non-small cell lung cancer less than  months after developing stage  or recurrent incurable disease will be considered study eligible by the criterion of having received one line of chemotherapy for non-small cell lung cancer.
Patients with single or multiple lung metastases at diagnosis or that develop over the course of treatment
Patient's index tumor(s) is primary lung cancer.
Patient has uncontrollable primary or metastatic disease outside of the lung.
Subjects must have a clinically indicated need for systemic chemotherapy for adenocarcinoma of the lung based on the investigator's assessment
NO prior chemotherapy for current diagnosis of lung cancer
NIH lung score 
Patients with diagnosis of advanced cancer with lung metastases; patients with no prior therapy are eligible if there is no known superior alternative medical therapy; for phase Ib expansion cohort diagnosis of osteosarcoma, lung metastases will be required
Patients with advanced cancer with resectable lung metastases
Patients with unresectable lung metastases
LUNG (ONLY APPLIES TO PATIENTS WITH PRIMARY OR METASTATIC LUNG LESIONS NOT PREVIOUSLY TREATED WITH RT):
Patients with suspected lung cancer with nodules in the lung or liver (- cm in diameter) will be eligible for this study.
The donor has existence or recent history of persistent pulmonary infiltrates, recent pneumonia, recent bronchitis, recurrent lung infections, or history or evidence of any lung disease including asthma, or current symptoms of upper respiratory tract infection
Restrictive lung diseases due to parenchymal damage (eg idiopathic lung fibrosis) or pleural adhesions. Patients with lung resection, scoliosis or thorax malformations can be included provided adequate spirometry testing during screening (eg FEV-Forced expiratory volume  ? %; age, sex and height adapted vital capacity)
Patients who have had prior radiation to the lung will be excluded from the study, although mediastinal irradiation will be permitted if minimal lung is in the treatment volume
Patients with surgery for a prior ipslilateral lung cancer are excluded
V =< % of total lung volume
Atelectasis of the entire lung
Patient must have a completed D plan and the attending physician must have reviewed and approved the dose volume histograms as follows: total lung volume percentage receiving at least  Gy (V) =< %, and mean lung dose =<  Gy
EGFR GERMLINE MUTATION TESTING: One of the following criteria:\r\n* Personal history of invasive lung cancer or one of the pre-invasive histologies associated with the development of lung cancer (adenocarcinoma in situ [AIS], minimally invasive adenocarcinomas [MIA] or atypical adenomatous hyperplasia [AAH]) and more than two affected family members with invasive lung cancer or one of the pre-invasive histologies associated with the development of lung cancer; OR\r\n* First-degree relatives of an individual enrolled in the study with a known EGFR germline mutation
Prior systemic anticancer therapy for metastatic squamous cell lung cancer
Prior radiation to lung fields
Lung disease unrelated to underlying malignancy.
No prior history of VAT or open lung surgery (on the lung in which the procedure will be performed);
Significant symptomatic deterioration of lung function.
If diagnosed with lung cancer, must have completed definitive treatment more than  months prior
Prior surgery or chemotherapy for this presentation of lung cancer (history of prior lung cancer that has been treated and deemed inactive by the clinician is acceptable; recurrent tumors may be treated on protocol as long as SBRT will be the definitive treatment)
Prior surgery for the current or another lung cancer is allowed as is prior radiation therapy
Prior systemic therapy for lung cancer
Prior therapy, with the intent to treat, the current diagnosis of lung cancer
Patients that have endobronchial lung cancer that is obstructive or hemorrhagic, but do not wish to undergo PDT therapy will be eligible to participate in the non-treatment group
Presence of metastatic disease in other locations in addition to the lung.
Any current smoker who meets the Centers for Medicare and Medicaid Services (CMS) eligibility criteria for lung cancer screening will be eligible for our intervention; thus, patients with a history of lung and/or other cancer(s) (who do not have current signs or symptoms of lung cancer) will be eligible
Past history of any lung cancer
Patients who have had more than  weeks of chemotherapy or radiation for this diagnosis of lung cancer
NIH lung score 
Scheduled for low dose computed tomography (CT) screening for lung cancer
Diagnosis of cancer, with evidence of primary or secondary lung involvement
Participant must have a lung or gastrointestinal (GI) primary cancer diagnosed in the last  months
Patients need lung isolation for purposed surgery
History of lung cancer
Passage through non-aerated lung or tissue
Subject has significant trapped lung, or a proximal bronchial obstruction which is likely to lead to trapped lung. For a subject to be eligible for this study,  separate study center clinicians must agree that there is no significant trapped lung on the same CXR using visual estimation (reference guide). The CXR used to make this decision must have been performed ? days preceding the consent form being signed, and must have been performed preferably on the same day, but no more than  calendar days after a pleural drainage. Significant trapped lung is deemed present if any  of the following criteria is met:
Cancer care continuum points are defined as follows:\r\n* Diagnosis: A lung cancer patient who has received diagnosis within the last  days but has not yet started treatment\r\n* Treatment: A lung cancer patients who has started initial treatment (chemotherapy, radiation, surgery) for diagnosis within the last  days, is actively receiving treatment, and has a prognosis of more than one year\r\n* Survivorship: A lung cancer patient who has completed treatment and who is clinically disease free at the time of caregiver enrollment to study\r\n* End of Life: A lung cancer patient who is estimated to have  months or less to live
PATIENTS: Scheduled to undergo surgery with lung resection for treatment of primary or secondary neoplasms of the lung
No patients who have received neoadjuvant therapy (chemo- or radio-therapy) for this lung cancer
No locally advanced or metastatic cancer requiring systemic therapy within  years prior to registration; no secondary primary lung cancer diagnosed concurrently or within  year prior to registration
No patients with recurrence of lung cancer after prior resection
Patients who are or become ineligible as defined by USPSTF guidelines for lung cancer screening.
Reports at least one year of lung cancer screening experience
Seeking baseline or annual follow-up low dose computed tomography (LDCT) lung cancer screening
Any prior investigational immune therapy, such as for lung cancer prevention or treatment or for CIS of the cervix
Meets guidelines for lung cancer screening, as determined by radiology team.
Individuals who have registered to undergo lung cancer screening and who agree to be called for possible participation
Lung carcinoma:
Not received radiation to the lung fields within the past  weeks.
Confirmed diagnosis of adenocarcinoma lung cancer OR,
Known Folate Receptor-negative lung nodules
Lung function assessment required for pre-surgical evaluation at the discretion of the cardiothoracic surgeon
Subjects with suspected sarcoidosis, lymphoma, or metastatic cancer from other sites (i.e. those without a known or suspected lung primary)
Patients receiving SBRT lung treatment and who have any one of the following high risk features:\r\n* Lung lesion >  cm\r\n* Diffusing capacity of the lungs for carbon monoxide (DLCO) < %\r\n* Forced expiratory volume, first second (FEV) < . L\r\n* Central lung tumors (defined as within  cm from the proximal bronchial tree)\r\n* Tumors that abut the great vessels, trachea, spinal cord, or esophagus\r\n* Prior lobectomy or pneumonectomy\r\n* Prior lung radiation (SBRT or conventional definitive lung radiation)
Patients undergoing guided-bronchoscopy for diagnosis of peripheral lung lesion/s >  and <  cm in diameter located in the outer / of the lung fields
Patient is planning to undergo radiation therapy for primary or recurrent carcinomas of the lung or oligo-metastatic carcinoma of the lung
Histologically confirmed lung cancer, or clinically diagnosed lung cancer
Adult (age ?  years) subjects with peripheral lung lesions that are <. cm in size who are planning to undergo percutaneous image guided lung biopsy as part of their routine medical care.
Inclusion Criteria:\n\n        The target population includes adults with small lung nodules that may represent a new\n        diagnosis of lung cancer, who typically would be managed by CT surveillance in usual\n        clinical practice. Thus, we will enroll all patients:\n\n          -  aged ? years\n\n          -  at least one nodule measuring ? mm in average diameter on chest CT.\n\n        Exclusion Criteria:\n\n          -  Pregnant Women\n\n          -  Age < years\n\n          -  Known diagnosis of cancer (except non-melanoma skin cancer) within  years
Participant must have histologically confirmed lung cancer and be deemed an appropriate surgical candidate for thoracoscopic lung resection and will have consent for a sentinel lymph node mapping by their oncologic surgeon; these patients will have invasive non-small cell lung cancers for which thoracoscopic mediastinal lymph node dissection at the time of thoracoscopic lung resection is standard of care; the extent of lung resections in potential trial patients could span from sublobar resection (i.e. wedge resection) to pneumonectomy, though it is anticipated that most patients will be undergoing the most common anatomic operation for lung cancer which is lobectomy; all stages of lung cancer that would otherwise be undergoing thoracoscopic lung resection and mediastinal lymph node dissection would be eligible
Subjects with suspected sarcoidosis, lymphoma, or metastatic cancer from other sites (i.e. those without a known or suspected lung primary)
Patients whose targeted lung lesion is visualized with fluoroscopy
Patients who have had a prior lung cancer within the last five years from the current diagnosis
Patients with any prior systemic therapy for the current diagnosis of lung cancer
Previous history of lung cancer
Receiving treatment for advanced lung cancer for over one month before enrollment; OR
Ever diagnosed with lung cancer
Primary or metastatic lung tumor located in central lung or near vertebral body
Patients planning to undergo radiation therapy for primary or recurrent carcinomas of the lung or cancer that is metastatic to the lung.
Uncontrolled lung disease
